The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.
The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.
Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating cognitive impairment (CI) associated with Huntington’s Disease (HD) failed to...
The S&P 500 Index ($SPX ) (SPY ) Wednesday closed down -0.74%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.06%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.70%. US stock...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.36%. US stock indexes today are...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.62%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.50%. US stock indexes today are...
A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...
The pharmaceutical company's growth prospects have taken a big hit.
/PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sage...